Glenmark Pharmaceuticals Ltd (NSE: GLENMARK): The rise in the share of Glenmark Pharmaceuticals Ltd came after the company received a clean report in the Good Manufacturing Practice (GMP) inspection conducted by the US Food and Drug Administration (US FDA) at its manufacturing facility in Aurangabad.
A Brokerage Firm Gave A Target Of 1,900
The company said in an exchange filing that the inspection was conducted between 9 and 20 September 2024. In the aftermath, the world-renowned broker Investec has suggested a “fast long in the stock with the target of 1,900 rupees which suggests a possible upside of 17 percent.
Glenmark Pharmaceuticals Ltd share has gained 115 percent over the last year and has experienced gains of 101.5 % so far this year. The stock has gained 81.4% in the previous 6 months.
From a technical perspective, the stock is above all important exponential moving averages and near 46.5 on the Relative Strength Indicator (RSI) which indicates the mid-range level of the indicator.
Glenmark Pharmaceuticals Ltd has a PE ratio 36.88, and its EPS is 46.47. The company is listed with a market cap of 46,187.15 crore rupees and it is placed 12th.
The PB ratio is 5.89 and the dividend yield is 0.15%. All these metrics make the company an attractive option for investors.
The brokerage firm said that the closure of the company’s Aurangabad facility with zero observations provides positive signals in the near term. This could ensure that the company continues to grow the company’s profits and cash flows.
Glenmark Pharmaceuticals Ltd is now becoming more relevant as India and other regions contribute over 70% of EBITDA.
Quick Fact
| Company name | Glenmark Pharmaceuticals |
|---|---|
| Highest share price | ₹1,769 |
| US FDA inspection | Passed (Aurangabad plant) |
| Inspection dates | 9-20 September 2024 |
| Possible target price | ₹1,900 |
| Possible upside | 17% |
| 1-year gain | 115% |
| Year-to-date gain | 101.5% |
| 6-month gain | 81.4% |
| RSI level | 46.5 |
| PE ratio | 36.88 |
| EPS | 46.47 |
| Market cap | ₹46,187.15 crore |
| Rank by market cap | 12th |
| PB ratio | 5.89 |
| Dividend yield | 0.15% |
| EBITDA contribution | India & other regions (70%) |
Disclaimer: The website and its content are for informational purposes only and should not be considered investment advice.
